PARIS, May 22, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced 30-day data demonstrating that treatment with the Edwards SAPIEN 3 valve in more than 450 commercial centers around the U.S. show consistently positive patient outcomes. The […]
Coronary/Structural Heart
Five-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions
PARIS, May 22, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott’s fractional flow reserve (FFR) diagnostic tool in combination with medical therapy compared to patients […]
Robocath demonstrates safety and efficacy of its R-OneTM medical robotic platform
100 percent technical success and no Major Adverse Cardiac Events (MACE) scored in first pre-clinical randomized trial Rouen, France, May 22, 2018 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today during the EuroPCR congress that its first robotic solution, […]
NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access
LAKE FOREST, Calif.–(BUSINESS WIRE)–NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function. This patient, along with 15 others treated to date under compassionate use protocols for severe tricuspid regurgitation, have received […]
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
First-of-its-Kind Lesion Preparation Tool Fractures Calcium in CAD with Sonic Pressure Waves, Enabling Optimal Stent Delivery and Expansion While Minimizing Trauma First Patient Enrolled in DISRUPT CAD II Post-Market Study Fremont, Calif. — May 21, 2018 — Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced […]
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., May 21, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the design of its pivotal Phase 3 EXPLORER-HCM clinical trial to evaluate the use of mavacamten for the potential […]
Edwards Announces Key Events For EuroPCR 2018
PARIS, May 21, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced key events for the company during EuroPCR 2018, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of […]
CHF Solutions to Exhibit at Heart Failure 2018 in Vienna, Austria
EDEN PRAIRIE, Minn., May 17, 2018 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq:CHFS), today announces that it will be exhibiting at the Heart Failure Meeting from May 26-29, 2018 in Vienna, Austria. This annual congress is organized by the Heart Failure Association of the European Society of Cardiology and draws approximately […]
CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC® Device
TORONTO, May 17, 2018 (GLOBE NEWSWIRE) — CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced completion of patient enrollment in a large scale, investigator sponsored trial (“CONDI 2”) to further assess […]
Teleflex to Introduce the New TrapLiner® Catheter in Europe and Showcase the Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump (IABP) at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) 2018
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care, urology and surgery, coronary and peripheral interventions, will showcase its complex PCI product portfolio and the Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump (IABP) at the EuroPCR being held in Paris, France on May 22 – […]



